Module 3: Implementing Bispecific T-Cell Engagers Into Practice: Moderated Panel Discussion

  • Introduction to BTCEs
  • The Patient Journey
  • Practice Settings
  • Multidisciplinary Education
  • CRS and ICANS Monitoring
  • Leveraging the EMR
  • Formulary Decisions
  • REMS Certification
  • Summary

After completing this activity, the participant should be better able to:

•       Identify solutions to streamline care coordination for patients receiving bispecific T-cell engager (BTCE) therapy across diverse practice settings.

•       Employ multidisciplinary strategies to enhance the safe integration of BTCEs in clinical workflows.

•       Emphasize the importance of patient and caregiver education for early recognition and management of toxicities.

•       Examine institutional approaches to formulary decisions, education initiatives, and cost considerations for BTCEs.

•       Outline the role of advanced practitioners in supporting BTCE implementation and long-term patient monitoring.

Megan May, PharmD, BCOP, FHOPA, FAPO

Baptist Health Lexington’s Cancer Center

Megan May is a Clinical Oncology Pharmacy Specialist at Baptist Health Lexington’s Cancer Center in Lexington, Kentucky. She received her Doctor of Pharmacy from Samford University’s McWhorter School of Pharmacy in Birmingham, Alabama, and completed a Pharmacy Practice Residency at Shands Jacksonville Medical Center and a Hematology/Oncology Pharmacy Residency at the Medical University of South Carolina. She is a Board-Certified Oncology Pharmacist. In addition to direct patient care, Dr. May plays an active role in the education of pharmacy students and residents. She has been involved at the national level with a number of professional organizations on various committees and positions over the years. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

Megan May, PharmD, BCOP, FHOPA, FAPO, has the following financial relationships to disclose, Amgen, AstraZeneca, Advisory board: Amgen, Consultant: Amgen

C. Brooke Adams, PharmD, BCOP

Orlando Health Cancer Institute

C. Brooke Adams is a board-certified Clinical Pharmacy Specialist in Malignant Hematology, Stem Cell Transplantation, and Cellular Therapy and the PGY-2 Oncology Residency Program Coordinator at the Orlando Health Cancer Institute. She completed her Doctorate of Pharmacy with research concentration at East Tennessee State University and her PGY-1 pharmacy practice and PGY-2 oncology residencies at Indiana University Health. She is a preceptor for UF and LECOM pharmacy students, PGY-1 and PGY-2 residents and is extensively involved in the education of hematology/oncology fellows and advanced practice providers. She is an active member of HOPA, FLASCO, NCODA, the OPN-FL Chapter, and ASTCT. She recently received the New Practitioner Award from HOPA in 2023 and is a member of the 2022 class of 40 under 40 in cancer presented by AVBCC.

C. Brooke Adams, PharmD, BCOP, has the following financial relationships to disclose, Pfizer, Genmab/AbbVie, Incyte, BMS, Advisory board: Genmab/AbbVie, Amgen, GSK, Johnson & Johnson, Consultant: BMS, Johnson & Johnson.

Emilie Aschenbrenner, PharmD, BCOP

Medical College of Wisconsin

Emilie Aschenbrenner is a board-certified Clinical Pharmacist in Stem Cell Transplantation and Cellular Therapy and the Hematology Clinical Coordinator at Froedtert and the Medical College of Wisconsin. She completed her Doctorate of Pharmacy at the University of Wisconsin, Madison and her PGY-1 pharmacy practice residency at Froedtert Hospital. She is a preceptor for PGY-1 and PGY-2 residents. She is an active member of HOPA, NCODA, Pharmacy Society of Wisconsin, and ASTCT and recently served on the CTN Pharmacy Research Committee. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

Emilie Aschenbrenner, PharmD, BCOP, has the following financial relationships to disclose, BMS, Astellas, Incyte, Genmab/AbbVie, Sanofi, BeiOne, Amgen, Advisory board: Amgen, Regeneron, Syndax

Katie Marcucci, DMSc, PA-C, CPAAPA

Tennessee Oncology

Katie Marcucci is a PA-C at Tennessee Oncology in Nashville, TN, specializing in malignant hematology. With 14 years of experience across multiple specialties, she currently cares for patients with blood cancers using both traditional and novel therapies. Passionate about education, Katie is an AAPA-certified preceptor and adjunct professor at several PA programs in her home state of Tennessee. She earned her Master’s in PA Studies from the University of New England in 2011 and a Doctor of Medical Science in clinician education from A.T. Still University in 2024. Katie’s commitment to patient care and teaching defines her impactful career.

Katie Marcucci has no relevant financial relationships to disclose.

Key:

Complete
Failed
Available
Locked
Implementing Bispecific T-Cell Engagers Into Practice: Moderated Panel Discussion - Pretest
5 Questions  |  Unlimited attempts  |  0/5 points to pass
5 Questions  |  Unlimited attempts  |  0/5 points to pass
BTCEs - Moderated Panel Discussion
Open to view video.  |  108 minutes
Open to view video.  |  108 minutes
Implementing Bispecific T-Cell Engagers Into Practice: Moderated Panel Discussion - Post test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
BTCE Moderated Panel Discussion Evaluation
17 Questions
17 Questions Please review and answer all the required questions.
CE Certificates: Panel Discussion
Up to 1.00 CE credits available  |  Certificate available
Up to 1.00 CE credits available  |  Certificate available
Implementing Bispecific T-Cell Engagers Into Practice: Moderated Panel Discussion - Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available